Free Republic

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 RADNOR, Pa., March 29, 2021 /PRNewswire/ -- NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF,OTCQB:RLFTF). Across all patients and sites, ZYESAMI™ met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and...

New Drug Promises “Rapid Recovery From Respiratory Failure”“Overall, 81% of RLF-100™-treated patients survived beyond 60 days, compared to 17% of control patients.” Oct 13, 2020 GENEVA and RADNOR, Pa., Oct. 13, 2020 /PRNewswire/ – RELIEF THERAPEUTICS Holding AG and NeuroRx, Inc., today announced topline results from 45 patients assessed in an open-label prospective study where 21 patients admitted to an intensive care unit (ICU) with critical COVID-19 and respiratory failure were treated with RLF-100™(aviptadil) and compared to 24 control patients treated in the same setting. All patients had severe comorbidities that rendered them ineligible for the ongoing randomized controlled phase...

NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19 Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients. At FDA's request, NeuroRx is submitting an expanded access policy enabling physicians to request RLF-100 for patients who meet this criterion. June 24, 2020 01:30 AM Eastern Daylight Time RADNOR, Pa. & GENEVA--(BUSINESS WIRE)--NeuroRx, Inc. (OTC:RLFTF), in partnership with RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” today announced that...